Cancer News

Mosunetuzumab: A Review - Promising New Therapy for Lymphoma

Apr 3, 2023 3:30:29 PM / by Elizabeth Budde, MD, PhD

How effective is mosunetuzumab in treating lymphoma? - [Slides] Elizabeth Budde, MD 2023 reviews new therapies - Synopsis below extracted from the video transcript.

 

Mosunetuzumab is a promising new therapy for the treatment of lymphoma that has shown significant effectiveness in early clinical trials. Dr. Elizabeth Budde presented an overview of the drug at a recent conference, highlighting its potential to improve patient outcomes.

 

Lymphoma is a type of cancer that affects the lymphatic system, which is responsible for fighting infections and diseases. Traditional treatments for lymphoma include chemotherapy, radiation, and stem cell transplants, which can be effective but also have significant side effects. Mosunetuzumab is a type of immunotherapy that works by targeting a protein called CD20, which is found on the surface of certain types of lymphoma cells.

 

Read The Full Transcript and Watch The Video Here

 

Early clinical trials of mosunetuzumab have shown promising results. In one study, 60% of patients with diffuse large B-cell lymphoma who had failed other treatments achieved a complete response, meaning there was no detectable cancer in their bodies. In another study, 64% of patients with follicular lymphoma achieved a response to the drug.

 

The drug is administered through intravenous infusion and has been well-tolerated by patients, with only mild to moderate side effects reported. However, larger and longer-term clinical trials are needed to confirm its safety and effectiveness.

 

In addition to its potential as a standalone therapy, mosunetuzumab also has the potential to be used in combination with other treatments. For example, it could be used in combination with checkpoint inhibitors, which are another type of immunotherapy that can help boost the immune system's ability to fight cancer.

 

Overall, mosunetuzumab is an exciting new therapy for the treatment of lymphoma that has shown significant promise in early clinical trials. As more data becomes available, it will be important to continue to evaluate its safety and effectiveness, as well as its potential use in combination with other treatments.

Topics: City of Hope, Mosunetuzumab, Immunotherapy, CAR T-cell, Lymphoma

Elizabeth Budde, MD, PhD

Written by Elizabeth Budde, MD, PhD

Elizabeth Budde, MD, PhD, is a highly accomplished physician-scientist who currently serves as an assistant professor in the department of hematology and hematopoietic cell transplantation at the City of Hope National Medical Center in California. Dr. Budde is a leading expert in the field of hematologic malignancies, with a focus on lymphomas and leukemias.

Subscribe to Email Updates

Recent Posts